(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 6.47% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.1%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Johnson & Johnson's revenue in 2026 is $96,362,000,000.On average, 27 Wall Street analysts forecast JNJ's revenue for 2026 to be $245,377,254,721,914, with the lowest JNJ revenue forecast at $236,460,923,061,330, and the highest JNJ revenue forecast at $258,419,556,270,792. On average, 27 Wall Street analysts forecast JNJ's revenue for 2027 to be $261,984,644,604,843, with the lowest JNJ revenue forecast at $249,207,136,922,775, and the highest JNJ revenue forecast at $280,159,132,735,893.
In 2028, JNJ is forecast to generate $280,349,302,876,602 in revenue, with the lowest revenue forecast at $262,061,675,547,915 and the highest revenue forecast at $303,027,693,960,393.